UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates.
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of...
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (œUNITY) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Bio Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more...
Patients with wet age-related macular degeneration who added Unity Biotechnology’s retinal disease med on top of Regeneron’s Eylea maintained their vision gains achieved with the blockbuster-approved therapy alone—but they didn’t experience any major gains that the biotech was hoping for.
Unity Biotechnology has concluded subject enrolment in its Phase II ENVISION clinical trial of UBX1325 in wet age-related macular degeneration (AMD) patients.